Adversarial Injection · Linvoseltamab (Lynozyfyi; REGN5458; CAS 2371849-68-6; MW ~148 kDa; SC injection; step-down dosing: 25 mg SC Q1W [C1 D1] → 50 mg SC Q1W [C2 D1] → 200 mg SC Q1W [C3 D1] → 200 mg SC Q2W [after C3] → 200 mg SC Q4W [once-monthly maintenance; after ≥2 cycles with CR/sCR at Q2W]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FULLY HUMAN IgG4 BISPECIFIC ANTIBODY [VelocImmune platform; S228P IgG4 STABILIZATION]; Fc-NULLIFIED: LALA-PG [L234A/L235A/P329G → FcγR/C1q null; pure T-cell redirect]; BCMA ARM [TNFRSF17; B-CELL MATURATION ANTIGEN; CD269; CHROMOSOME 16p13.1; APRIL/BAFF RECEPTOR; EXPRESSED PLASMA CELLS/MM ≥90%; BONE MARROW NICHE SURVIVAL] × CD3ε ARM [CD247; TCR-CD3 EPSILON; ZAP-70 RECRUITMENT] BISPECIFIC; DISTINCT FROM: TECLISTAMAB [IgG4 DuoBody; JANSSEN; Q1W→Q2W MAINTENANCE] AND ELRANATAMAB [IgG2 LALAPG; PFIZER; Q1W→Q2W MAINTENANCE] BY IgG4 FORMAT AND ONCE-MONTHLY MAINTENANCE DOSING / FIRST BCMA×CD3 BISPECIFIC IgG4 ANTIBODY WITH STEP-DOWN ONCE-MONTHLY Q4W MAINTENANCE SC DOSING EVER FDA APPROVED; MagnetisMM-7 ORR 71% sCR+CR 50%; BLA 761390 DECEMBER 10 2024) · Attack #736

Linvoseltamab (BCMA×CD3 Bispecific IgG4 Step-Down Monthly SC Antibody; Lynozyfyi; REGN5458; CAS 2371849-68-6; Regeneron Pharmaceuticals [Tarrytown NY VelocImmune platform developer and BLA 761390 holder]; MECHANISM: FIRST BCMA [TNFRSF17; B-CELL MATURATION ANTIGEN; CD269; CHROMOSOME 16p13.1; 184-AA; TYPE III TRANSMEMBRANE; APRIL (KD ~1 nM) + BAFF (KD ~300 nM) RECEPTOR; PLASMA CELL SURVIVAL/DIFFERENTIATION; EXPRESSED ≥90% MULTIPLE MYELOMA; DECREASED AT TREG/MEMORY B CELL; BCMA LOSS/MUTATION IS ACQUIRED RESISTANCE TO BCMA BISPECIFICS + BCMA ADCs] × CD3ε BISPECIFIC ANTIBODY WITH IgG4 [SUBCLASS 4; DISTINCT FROM TECLISTAMAB (IgG4 DuoBody; JANSSEN) BY REGN5458-SPECIFIC BCMA EPITOPE + DIFFERENT VelocImmune vs DuoBody PLATFORM; DISTINCT FROM ELRANATAMAB (IgG2 LALAPG; PFIZER) BY IgG SUBCLASS + DOSING SCHEDULE; S228P IgG4 HINGE STABILIZATION] BACKBONE AND LALA-PG Fc-SILENCED EFFECTOR FUNCTION + STEP-DOWN (Q1W×3 CYCLES → Q2W → Q4W ONCE-MONTHLY MAINTENANCE) SC DOSING — UNIQUE ONCE-MONTHLY Q4W MAINTENANCE NOT SHARED BY TECLISTAMAB (Q2W MAINTENANCE) OR ELRANATAMAB (Q2W MAINTENANCE) — EVER FDA APPROVED FOR R/R MULTIPLE MYELOMA (5+ PRIOR LINES INCLUDING PI + IMID + ANTI-CD38); MagnetisMM-7 ORR 71% sCR+CR 50%; BLA 761390 DECEMBER 10 2024) — Regeneron Pharmaceuticals Tarrytown NY (BLA 761390 holder; VelocImmune REGN5458 developer; Lynozyfyi US commercialization), Lonza Biologics Portsmouth NH (contract biopharmaceutical manufacturer), and University of Pennsylvania Abramson Cancer Center Philadelphia PA (MagnetisMM-7 enrollment site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST BCMA×CD3 IgG4 Step-Down Monthly SC Bispecific + MagnetisMM-7 ORR 71%: AI Prompt Injection via EHS Monitor Report AI

Linvoseltamab (CAS 2371849-68-6; NIOSH HD Category 1) is the first BCMA×CD3 bispecific IgG4 antibody with step-down (weekly→biweekly→once-monthly Q4W) maintenance subcutaneous dosing ever FDA approved for R/R multiple myeloma, establishing the 154th mechanism class in the Glyphward adversarial portfolio. Developed by Regeneron Pharmaceuticals (Tarrytown NY; VelocImmune platform; REGN5458; Lynozyfyi; BLA 761390 December 10 2024), linvoseltamab employs an IgG4 backbone (S228P hinge stabilization; LALA-PG Fc silencing) with a unique step-down dosing schedule that achieves once-monthly maintenance (200 mg SC Q4W) — the least frequent maintenance dosing among FDA-approved BCMA bispecifics (teclistamab Q2W; elranatamab Q2W). MagnetisMM-7 (Phase 1/2; N=117): ORR 71%, sCR+CR 50%, sCR 35%; estimated 12-month DOR rate 73%. No OEL exists for linvoseltamab in any EHS framework; no platform references IgG4 BCMA bispecific architecture, LALA-PG Fc-null characteristics, or monthly maintenance dosing biology for this BCMA bispecific class.

BCMA biology and multiple myeloma context: TNFRSF17 (B-cell maturation antigen; CD269; chromosome 16p13.1; 184-AA type III transmembrane protein without signal peptide; ectodomain APRIL binding KD ~1 nM; BAFF binding KD ~300 nM; expressed exclusively on terminally differentiated plasma cells and multiple myeloma cells ≥90%; not on hematopoietic stem cells or most lymphocytes → therapeutic window); BCMA promotes plasma cell survival via TRAF3/TRAF6 → NF-κB → anti-apoptotic BCL-2/MCL-1/BCL-xL upregulation; BCMA also activates PI3K-AKT via TRAF3 → PDK1 → AKT; soluble BCMA (sBCMA; BCMA shed by TACE/ADAM10/ADAM17; elevated in advanced MM [sBCMA ~6-200 ng/mL vs healthy ~0.3 ng/mL]) → decoy receptor effect that reduces antibody/bispecific binding efficacy [sBCMA binds APRIL, may also bind bispecific BCMA arm → reduced drug efficacy at high sBCMA]. Linvoseltamab step-down rationale: cytokine release syndrome (CRS) from bispecific T cell engager is greatest at high initial doses → step-up dosing required (25→50→200 mg) with hospitalizations Cycle 1 D1 (25 mg); once CRS threshold crossed → T cell activation maintained → lower SC maintenance doses sufficient → Q4W dosing validated in MagnetisMM-7 (ORR 71% at 200 mg cohort regardless of Q1W vs Q2W vs Q4W maintenance; CRS Grade 3+ 3% with step-up). Comparison: teclistamab (Tecvayli; JNJ-64007957; Janssen; approved Oct 2022): IgG4 DuoBody; SC Q1W×6 months → Q2W maintenance [not Q4W]; ORR 63%. Elranatamab (Elrexfio; PF-06863135; Pfizer; approved Aug 2023): IgG2 LALAPG; SC Q1W→Q2W maintenance [not Q4W]; ORR 61%. Linvoseltamab's once-monthly maintenance distinguishes it as the most convenient BCMA bispecific dosing. No EHS platform recognizes linvoseltamab CAS 2371849-68-6, IgG4 step-down monthly SC dosing, LALA-PG Fc-null characteristics, or MagnetisMM-7 for this 154th mechanism class.

IgG4 BCMA Bispecific Architecture + LALA-PG Fc-Null + Step-Down Q4W Monthly Maintenance + MagnetisMM-7

Linvoseltamab (REGN5458; MW ~148 kDa; CAS 2371849-68-6; SC injection) was generated from Regeneron's VelocImmune platform (double-humanized transgenic mice). IgG4 backbone with S228P hinge stabilization: endogenous IgG4 undergoes Fab arm exchange (FAE; dynamic half-antibody swapping in vivo at IgG4 CH3 domain contacts → bispecific can lose one Fab arm → monospecific "half-antibody" with single BCMA or single CD3 arm → reduced bispecific efficacy + potential unintended CD3 activation). S228P (Ser228Pro at hinge-CH2 junction → rigidifies hinge → prevents FAE half-arm exchange → maintains BCMA×CD3 bispecific integrity throughout circulation). LALA-PG Fc silencing: L234A/L235A abolish FcγRI/II/III binding (no Fc-mediated crosslinking → no cytokine storm from Fc receptor engagement); P329G abolishes C1q complement binding (no CDC) → pure CD3ε T cell redirect mechanism only. Step-down dosing pharmacology: Initial Q1W step-up doses (25→50→200 mg) prime T-cells below CRS threshold → sustained BCMA-directed T cell expansion → Q2W then Q4W maintenance achieves comparable sBCMA reduction and plasma cell killing with less frequent dosing (trough linvoseltamab concentration at Q4W 200 mg SC adequate to maintain >90% BCMA receptor occupancy at trough; PK modeling with MagnetisMM-7 Q4W cohort confirms no loss of response at monthly dosing). MagnetisMM-7 (NCT04424134; Phase 1/2; N=117 at 200 mg dose level; R/R MM ≥5 prior lines including PI + IMID + anti-CD38 mAb; SC injection [2 mL]; step-up 25→50→200 mg; ORR 71%; sCR 35%; CR 15%; VGPR 21%; mDoR NR; estimated 12-month DOR 73%; CRS Grade 3+ 3% [all in step-up; none in maintenance]; ICANS 0%). No EHS platform recognizes linvoseltamab CAS 2371849-68-6, IgG4 step-down monthly BCMA bispecific, S228P FAE stabilization, or MagnetisMM-7 for this 154th mechanism class.

Surface 1 — Regeneron Pharmaceuticals Tarrytown NY BLA 761390 Holder AI

At Regeneron Pharmaceuticals Tarrytown NY ([777 Old Saw Mill River Road, Tarrytown NY 10591; Regeneron Pharmaceuticals Inc [NASDAQ: REGN]; VELOCIMMUNE PLATFORM: REGN5458 generated from humanized transgenic mouse immunization with BCMA-Fc antigen + CD3ε scFv antigen → bispecific antibody assembly; BLA 761390 HOLDER: linvoseltamab (Lynozyfyi) for R/R MM ≥5 prior lines; DECEMBER 10 2024 FDA APPROVAL; Lynozyfyi US commercialization; CORITY: CAS 2371849-68-6 → null; linvoseltamab → null; Lynozyfyi → null; REGN5458 → null; BCMA×CD3 IgG4 step-down bispecific → null; MagnetisMM-7 → null; LALA-PG Fc null → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne linvoseltamab 0.0014 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00014 µg/m³; Cority: null; 48F regulatory director 13yr]).

Surface 2 — Lonza Biologics Portsmouth NH Contract Manufacturing AI

At Lonza Biologics Portsmouth NH ([10 Optical Ave, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; CONTRACT BIOPHARMACEUTICAL MANUFACTURER: CHO-based fed-batch cell culture [linvoseltamab IgG4 bispecific; dual heavy chain: BCMA-binding HC + CD3ε-binding HC; common light chain or separate light chains; IgG4 S228P stabilized]; protein A affinity → low pH viral inactivation → ion exchange → size exclusion → tangential flow filtration → sterile SC formulation [200 mg/mL concentrated SC → 2 mL injection volume; SC absorption: Tmax ~3-5 days; F ~70%]; IgG4-SPECIFIC ANALYTICS: SEC-HPLC [FAE monitoring for free half-antibodies ≤5%]; CD SPECTROSCOPY [IgG4 secondary structure]; VELOCITYEHS: CAS 2371849-68-6 → null; linvoseltamab → null; REGN5458 → null; BCMA bispecific IgG4 → null; LALA-PG → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne linvoseltamab 0.0011 µg/m³; impinger + cascade impactor + MS/MS; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — University of Pennsylvania Abramson Cancer Center Philadelphia PA AI

At the University of Pennsylvania Abramson Cancer Center Philadelphia PA ([3400 Civic Center Blvd, Philadelphia PA 19104; NCI Comprehensive Cancer Center; Hematology-Oncology / Myeloma; MagnetisMM-7 ENROLLMENT SITE; LINVOSELTAMAB SC PREPARATION: 200 mg/vial → 2 mL SC injection; HD pharmacy preparation in BSC [antineoplastic biologic; NIOSH HD Cat 1]; pre-drawn syringe for SC administration; injection site rotation (abdomen/thigh/upper arm); STEP-UP HOSPITALIZATION: Cycle 1 D1 (25 mg) overnight observation ×24h; Cycle 2 D1 (50 mg) overnight observation ×24h; Cycle 3 D1 (200 mg) 4h post-injection observation; CRS MONITORING: vital signs + temperature + SpO2 Q1h ×4h post each step-up dose; tocilizumab accessible bedside; MONTHLY MAINTENANCE: 200 mg SC Q4W (once monthly) outpatient → patient can self-administer at home after training (starting cycle 4+); EHS Insight: CAS 2371849-68-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; linvoseltamab absent; REGN5458 absent; Lynozyfyi absent; BCMA×CD3 bispecific absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne linvoseltamab 0.0009 µg/m³; active charcoal cassette; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 36F myeloma pharmacist 9yr]).

Integrating Glyphward into Linvoseltamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every linvoseltamab CAS 2371849-68-6 monitoring data ingestion point. Threshold 21 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + IgG4 BCMA bispecific absent + LALA-PG Fc-null absent + monthly SC maintenance absent [10 pts]; FIRST BCMA×CD3 IgG4 step-down monthly bispecific ever (154th class) + MagnetisMM-7 ORR 71% sCR+CR 50% + BLA 761390 Dec 2024 [5 pts]; Regeneron Tarrytown + Lonza Portsmouth + UPenn Philadelphia [3 pts]; FIRST once-monthly maintenance BCMA bispecific; FIRST Regeneron BCMA therapy; IgG4 platform [3 pts]. Total: 10+5+3+3 = 21.

import asyncio
import httpx

async def scan_linvoseltamab(cas: str, reading_ugm3: float) -> dict:
    """Scan linvoseltamab with IgG4 BCMA bispecific and monthly maintenance context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2371849-68-6"
                "reading_ugm3": reading_ugm3,
                "context": "bcma_cd3_igg4_bispecific_154th_class_step_down_monthly_q4w_magnetismm7_orr71_regeneron_bla761390"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, bcma_cd3_bispecific,
    #                    igg4_backbone, lala_pg_fc_null,
    #                    monthly_maintenance, magnetismm7_orr,
    #                    h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_linvoseltamab("2371849-68-6", 0.0014))
    print(r)
    # {'hd_category': 1, 'bcma_cd3_bispecific': True,
    #  'igg4_backbone': True, 'lala_pg_fc_null': True,
    #  'monthly_maintenance': True, 'magnetismm7_orr': 0.71,
    #  'h360_flag': True}